Please assess the completion status of the following clinical trial:

Trial Title: Propofol vs Propofol + Benzo/Opiates in High Risk Group

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide informed consent~* Age greater than or equal to 18 years~* Presence of at least 1 of the following criteria:~  1. ASA class 3 or higher~ 2. BMI of 30 or greater~ 3. At risk for OSA (score of 3 or greater on the STOP-BANG screening tool)~Exclusion Criteria:~* drug allergy to Propofol, Benzodiazepines, or Opioids~* patients who received Benzodiazepines or Opioids within 24 hours of the procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol+Benzo/Opioids (Type: ACTIVE_COMPARATOR): If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg
- Propofol Alone (Type: ACTIVE_COMPARATOR): The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~* Induction Dose: 2-2.5 mg/kg~* Maintenance Dose: 0.1-0.2 mg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).